Back to AI TrendsHealthcare Impact
The Synthetic Patient: Mantis Biotech is Building AI ‘Digital Twins’ to Break Medicine's Data Gridlock
TechCrunch AI March 30, 2026
Mantis Biotech is leveraging generative AI to create high-fidelity 'digital twins' of humans, effectively bypassing the privacy hurdles and data silos that stifle medical innovation. For leaders in life sciences and insurance, this represents a shift toward a 'flight simulator' model for R&D—slashing the time and capital required to validate new treatments by testing them on synthetic cohorts first.
Key Intelligence
- •Mantis uses AI to fuse disparate data sources into synthetic datasets that mirror human anatomy, physiology, and even behavior.
- •This 'digital twin' approach allows researchers to run thousands of simulations before a single biological subject is ever enrolled in a clinical trial.
- •By generating synthetic data, the platform solves the industry’s greatest bottleneck: the scarcity of high-quality, privacy-compliant patient records.
- •Apparently, these models are sophisticated enough to predict how specific demographics will respond to a drug, reducing the risk of late-stage trial failures.
- •The goal is to transition medicine from reactive testing to predictive modeling, potentially shaving years off the traditional 10-year drug development cycle.
- •Think of it as the ultimate stress test for biotech; if a treatment doesn't work on the digital twin, it’s a sign to pivot before burning through millions.